Interrogating cortical function with transcranial magnetic stimulation: insights from neurodegenerative disease and stroke by Agarwal, S et al.
Confidential: For Review Only
 
 
 
 
 
 
Interrogating cortical function with transcranial magnetic 
stimulation: Insights from neurodegenerative disease and 
stroke  
 
 
Journal: Journal of Neurology, Neurosurgery, and Psychiatry 
Manuscript ID jnnp-2017-317371.R3 
Article Type: Review 
Date Submitted by the Author: n/a 
Complete List of Authors: Agarwal, Smriti; University of Sydney Brain and Mind Research Institute 
Koch, Giacomo; Fondazione Santa Lucia IRCCS 
Hillis, A; Johns Hopkins Hospital 
Huynh, William; Brain and Mind Centre, ; Prince of Wales Clinical School,   
Ward, Nick; UCL Institute of Neurology, Sobell Department of Motor 
Neuroscience 
Vucic, Steve; The Brain Dynamics Centre, Westmead Millennium Institute; 
Sydney Medical School, University of Sydney 
Kiernan, Matthew C.; Prince of Wales Hospital, Institute of Neurological 
Sciences 
Keywords: 
MAGNETIC STIMULATION, STROKE, MOTOR NEURON DISEASE, DEMENTIA, 
PARKINSON'S DISEASE 
<b>Specialty</b>: Other 
  
 
 
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
Confidential: For Review Only
 
 
1
Title 1 
 2 
Interrogating cortical function with transcranial magnetic stimulation: Insights 3 
from neurodegenerative disease and stroke 4 
 5 
 6 
Article Type 7 
 8 
Review 9 
 10 
 11 
Authors 12 
 13 
Smriti Agarwal1, Giacomo Koch2 Argye E Hillis3, William Huynh1, Nick S Ward4, 14 
Steve Vucic5, Matthew C Kiernan1 15 
 16 
1. Brain and Mind Centre, University of Sydney, and Institute of Clinical Neurosciences, Royal Prince Alfred Hospital 17 
Sydney NSW 2050, Australia 18 
 19 
2. Non-Invasive Brain Stimulation Unit, Neurologia Clinica e Comportamentale, Fondazione Santa Lucia IRCCS, Rome, 20 
Italy; Stroke Unit, Department of Neuroscience, Policlinico Tor Vergata, Viale Oxford 81, 00133, Rome, Italy. 21 
 22 
3. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA;  23 
Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA;  24 
Cognitive Science, Johns Hopkins University, Baltimore, MD, 21218, USA. 25 
 26 
4. Sobell Department of Motor Neuroscience, UCL Institute of Neurology, University College London, 33 Queen Square, 27 
London WC1N 3BG, UK; 28 
The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; 29 
UCLPartners Centre for Neurorehabilitation, UCL Institute of Neurology, University College London, Queen Square, 30 
London WC1N 3BG, UK. 31 
 32 
5. Westmead Clinical School, University of Sydney, Sydney 2006, Australia 33 
 34 
 35 
Word count Abstract 208, main text 4775 (excluding table, figure legends and 36 
references) 37 
References 189 38 
Figures 3 (colour figures 3); Tables 1 39 
 40 
Corresponding author: 41 
 42 
Smriti Agarwal 43 
Visiting research fellow  44 
 45 
ForeFront | Kiernan Group 46 
The University of Sydney 47 
Brain and Mind Centre, Room 416  48 
Level 4, M02F, 94 Mallett Street Camperdown NSW 2050 49 
T +61 (2) 9114 4258 50 
F: +61 (2) 9114 4254 51 
E: smriti.agarwal@cantab.net 52 
 53 
 54 
 55 
Page 1 of 36
https://mc.manuscriptcentral.com/jnnp
Journal of Neurology, Neurosurgery, and Psychiatry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 
 
2
Abstract 56 
Transcranial magnetic stimulation (TMS) is an accessible, non-invasive technique to 57 
study cortical function in vivo. TMS studies have provided important 58 
pathophysiological insights across a range of neurodegenerative disorders and 59 
enhanced our understanding of brain reorganisation after stroke. In 60 
neurodegenerative disease, TMS has provided novel insights into the function of 61 
cortical output cells and the related intracortical interneuronal networks. 62 
Characterisation of cortical hyperexcitability in amyotrophic lateral sclerosis and 63 
altered motor cortical function in frontotemporal dementia, demonstration of 64 
cholinergic deficits in Alzheimer’s disease and Parkinson’s disease are key 65 
examples where TMS has led to advances in understanding of disease 66 
pathophysiology and potential mechanisms of propagation,, with the potential for 67 
diagnostic applications. In stroke, TMS methodology has facilitated the 68 
understanding of cortical reorganisation  that underlie functional recovery. These 69 
insights are critical to the development of effective and targeted rehabilitation 70 
strategies in stroke. The present Review will provide an overview of cortical function 71 
measures obtained using TMS and how such measures may provide insight into 72 
brain function. Through an improved understanding of cortical function across a 73 
range of neurodegenerative disorders, and identification of changes in neural 74 
structure and function associated with stroke that underlie clinical recovery, more 75 
targeted therapeutic approaches may now be developed in an evolving era of 76 
precision medicine. 77 
 78 
 79 
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 81 
 82 
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 85 
 86 
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Introduction 87 
The ability to modify human brain function is a long held scientific aspiration. 88 
Centuries ago, cognitive neuroscientists used torpedo fish and eels to electrically 89 
stimulate the brain, while more conventional electricity was first used for brain 90 
stimulation in the 18th century. It was only three decades ago that Pat Merton and 91 
colleagues [1] achieved electrical stimulation of the motor cortex through the intact 92 
scalp to generate a relatively synchronous muscle response. One of the issues with 93 
this methodology of transcranial electrical stimulation (TES), however, was the 94 
stimulation of pain fibres on the scalp. Subsequently, Barker and his team [2] 95 
became the first to use magnetic stimulation (TMS) in the human brain to achieve 96 
simultaneous muscle activity. Over 18000 scientific publications relating to TMS 97 
have appeared (http://www.webofknowledge.com, topic = “transcranial magnetic 98 
stimulation” search) since Barker’s first description, with over a third of these in the 99 
last 5 years alone, indicative of the pace at which the field is moving forward.  100 
The aim of the present Review is to provide the clinician with an overview of 101 
physiological considerations involved with TMS, including cortical output measures 102 
that provide important information regarding pathophysiological alterations in 103 
neurodegenerative disorders and post stroke reorganisation of neural structure and 104 
function. This Review aims to provide an overview of TMS applications and their 105 
utility in providing a functional understanding of disease mechanisms and the 106 
potential for development of novel diagnostic and prognostic tools in neurological 107 
disease. 108 
 109 
Measures of cortical function 110 
TMS induces current flows in the brain by application of a pulsed magnetic field 111 
leading to depolarisation of the underlying cortical neurons (Figure 1). The resultant 112 
electrical activity in the brain can be modified by the shape and orientation of the coil 113 
used, combined with underlying neuronal anatomy and orientation relative to the coil, 114 
magnetic pulse wave form, intensity, frequency and pattern of stimulation [3-6].  115 
The precise nature of the neuronal circuitry activated by TMS remains incompletely 116 
understood. Applying TMS over the motor cortex (Figure 2), generates a 117 
corticomotor neuronal volleys which may be a result of direct excitation of cortical 118 
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neurons (Direct or D-waves) or trans synaptic excitation (Indirect or I-waves). The I-119 
waves are thought to originate through a complex interaction between cortical output 120 
cells (Betz cells, layer V) and interneuronal cells [3,7-9].  121 
Following a brief overview of TMS output measures, their application as potential 122 
diagnostic and prognostic markers will be further considered.  123 
A widely used experimental paradigm involves application of TMS to the motor 124 
cortex with recording electrodes placed over an intrinsic hand muscle in the 125 
contralateral limb (Figure 2). The resultant motor-evoked potential (MEP) on 126 
electromyography (EMG) is typically recorded from the abductor pollicis brevis (APB), 127 
abductor digiti minimi (ADM) or the first dorsal interosseous (FDI) muscle. This 128 
paradigm can be applied to quantity excitability characteristics of the underlying 129 
motor cortex.  130 
 131 
Motor Threshold (MT) indicates the ease with which motor cortex output cells and 132 
corticomotor neurons can be excited. MT is thought to reflect the density of 133 
corticomotor neuronal projections onto the anterior horn cells. It thus, follows, that 134 
MTs tend to be lower in the dominant hand [10] and correlate with the performance 135 
of fine motor tasks [11]. MTs have the potential of providing a biomarker of cortical 136 
neuronal membrane excitability. Voltage gated sodium channels are critical to 137 
cortical axon excitability [12] while excitatory synaptic neurotransmission in the 138 
neocortex is mediated by the glutaminergic alpha-amino-3-hydroxy-5-methyl-4-139 
isoxazoleproprionic acid (AMPA) receptors [13]. Thus voltage gated sodium channel 140 
blocking drugs increase MT [14,15] while glutaminergic agonists decrease it [16]. 141 
Interestingly, neuromodulatory agents affecting GABA, dopaminergic, noradrenergic 142 
and cholinergic systems, do not affect the motor threshold [17]. 143 
MT was initially defined as the minimum stimulation intensity (% maximum stimulator 144 
output) required to achieve an MEP response of (amplitude >50 µV) in the target 145 
muscle in 50% of stimulus trials [18]. Evolving studies in threshold tracking TMS 146 
have led to redefinition of the MT as stimulus required to achieve and maintain a 147 
target MEP response of 0.2mV (± 20 %) [19,20]. MT tends to be lower in a 148 
voluntarily contracting muscle (active motor threshold, AMT) when compared to that 149 
in a muscle at rest (resting motor threshold, RMT) [21].  150 
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5
Single Pulse TMS measures 151 
Motor Evoked Potential (MEP) amplitude represents summation of descending 152 
corticospinal volleys onto motor neurons comprising of direct (D) and indirect (I) 153 
waves on to the spinal motor neurons [22,23]. Increasing MEP amplitude with 154 
increase in stimulus intensity generates a sigmoid stimulus response curve [21]. 155 
MEP may be represented as a percentage of peripheral stimulation derived 156 
compound muscle action potential (CMAP), to account for the lower motor neuron 157 
contribution.  158 
Although, the MEP reflects the density of corticomotor neuronal projections onto 159 
motor neurons similar to the MT, [24], the neurotransmitter pathways involved in the 160 
generation of the MEP are different. GABAergic agents acting via the GABAA 161 
receptor suppress the MEP while glutaminergic and noradrenergic agents increase 162 
the MEP amplitude [25,26].  163 
The main limitation in utilising the MEP response as a biomarker of cortical motor 164 
neuronal function is the significant intersubject and intertrial variability in MEP 165 
latency and amplitude [27].  166 
Central Motor Conduction Time (CMCT) is a measure of the time taken by a 167 
neural impulse to travel from the motor cortex to stimulate the spinal or bulbar motor 168 
neuron, and thus, is also indicative of the integrity of corticospinal tracts [28]. CMCT 169 
is an overall reflection of time to activation of the pyramidal cells and conduction time 170 
of neural impulses in the corticospinal tract. 171 
In TMS studies, CMCT is usually calculated using the F wave method or cervical 172 
nerve root stimulation method [29,30]. Both these methods measure the delay 173 
between the MEP latency and time to generate a response using peripheral 174 
stimulation. The key distinction between these two methods is the inclusion of the 175 
spinal motor neuron while measuring the peripheral stimulation time. In the F wave 176 
method, a peripheral nerve is supramaximally stimulated leading to antidromic 177 
stimulation which travels up the nerve root to the spinal motor neuron. This, in turn 178 
stimulates the efferent root orthodromically, generating an F wave. In the cervical 179 
nerve root stimulation, the peripheral conduction time is estimated as the time taken 180 
to generate a CMAP by directly stimulating the spinal nerve root. The CMCT can be 181 
variable with a range of physiological and subject dependent factors such as age, 182 
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6
gender, hand dominance and neck position  183 
Cortical Silent Period (CSP) refers to a transient cessation of voluntary activity on 184 
electromyography (EMG) in a target muscle measured after magnetic stimulation of 185 
the contralateral motor cortex. CSP is a reflection of GABAB receptor mediated 186 
cortical inhibition [31,32] and also appears to be influenced by the density of 187 
corticomotor neuronal projections onto the spinal motor neuron [27]. It is, thus, the 188 
longest in the upper limb muscles.  189 
CSP is calculated as the time interval between the onset of the MEP response and 190 
resumption of voluntary EMG activity following TMS [31], and increases with stimulus 191 
intensity.  192 
Paired Pulse TMS Paradigms 193 
Paired pulse techniques provide insights into functioning of intracortical excitatory 194 
and inhibitory circuits [27] by measuring the modulation of the cortical response to a 195 
test stimulus preceded by a conditioning stimulus. The two commonly applied paired 196 
pulse paradigms comprise are referred to as the constant stimulus [33] and threshold 197 
tracking [19] techniques. Either can be used to measure the short interval 198 
intracortical inhibition (SICI), long interval intracortical inhibition (LICI) and 199 
intracortical facilitation (ICF), each of which is an index of cortical motor function. 200 
Paired pulse TMS paradigms (Figure 2) used to determine the SICI and ICF consist 201 
of a subthreshold conditioning stimulus followed, at prespecified intervals (ISI), by a 202 
suprathreshold test stimulus. The constant stimulus paired pulse paradigms [33] 203 
measure the variation in MEP responses, while keeping the test and conditioning 204 
stimuli constant. Inhibition is observed at ISI of 0-5 ms facilitation at longer intervals 205 
between the stimuli. To overcome the issue of inherent MEP variability, which was 206 
used as an output measure in the constant stimulus protocols, threshold tracking 207 
protocols [19,34] were developed. These rely on using a fixed target amplitude MEP 208 
response and track the test stimulus intensity required to achieve this response. 209 
Higher stimulus intensity required to maintain this target response indicates inhibition 210 
while a lower intensity suggests facilitation. The target MEP response is chosen from 211 
the steepest part of the stimulus response curve (Figure 2c), thus reducing the 212 
variation in the outcome variable.  213 
Studies using cervical epidural electrode recordings suggest that SICI is associated 214 
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7
with a reduction in the amplitude of I waves in a temporal pattern consistent with 215 
inhibitory post synaptic potentials mediated via GABAA receptors [35,36]. Drugs 216 
potentiating GABAA receptor mediated neurotransmission, thus, increase the SICI. 217 
Other neurotransmitter systems may have an indirect role via modulation of GABAA 218 
receptors, as indicated by SICI alterations using glutaminergic agents, dopamine 219 
agonists and noradrenergic blockers [37,38]. The cortical signature of SICI is likely to 220 
be a combination of synaptic processes, inhibitory interneuronal interactions and 221 
axonal refractoriness [20,39-41]. 222 
The physiological processes driving ICF remain even less well understood. 223 
Interestingly, ICF is decreased by antiglutaminergic agents [37] and is not associated 224 
with changes in I waves [27] which coincide with SICI [15]. 225 
LICI occurs when a suprathreshold conditioning stimulus is followed by a test 226 
stimulus at an ISI of 50-300 ms [3]. LICI seems to be mediated via GABAB receptors 227 
[42,43]. 228 
Short latency afferent inhibition (SAI) is the suppression of TMS induced MEP 229 
response after peripheral nerve stimulation [44,45]. Thus, when a median sensory 230 
stimulation is administered approximately 20 ms prior to the TMS pulse over the 231 
contralateral motor cortex, the MEP response from the APB muscle is suppressed. It 232 
reflects inhibitory modulation of large sensory fibres on the motor cortex and is likely 233 
to involve central cholinergic transmission [46,47]. 234 
Repetitive TMS paradigms (rTMS) 235 
Repetitive TMS (rTMS) with applications of trains of TMS pulses over several 236 
minutes duration [48], produces cortical changes that last beyond the duration of 237 
stimulation, in a frequency dependent manner [14,49]. Simple rTMS protocols 238 
involve application of single stimuli at fixed interstimulus intervals (ISI) and their 239 
effects depend of the frequency of stimuli used. A low frequency stimulation (≤1Hz) 240 
depresses cortical excitability, while high frequency (5-20Hz) stimulation increases 241 
excitability (Figure 1). Patterned rTMS protocols utilise a combination of different ISIs, 242 
a common example of this being theta burst TMS (TBS), that incorporates triplet 243 
TMS pulses (bursts of 3 pulses at 50 Hz repeated at 200 ms intervals) to induce 244 
longer lasting effects than conventional rTMS protocols for a relatively shorter 245 
duration of application [50]. Continuous theta burst stimulation (cTBS), usually 246 
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8
involving trains of uninterrupted stimulation for 20-40 s, has an inhibitory effect on 247 
corticospinal excitability whereas intermittent theta burst stimulation (iTBS) has the 248 
opposite effect. 249 
At a larger scale, TMS may enhance the understanding of systems level changes in 250 
brain circuitry. The application of rTMS over a specified cortical region has effects on 251 
remote brain areas [51] that may modulate network activity in the brain leading to 252 
behavioural alterations not directly related to the area being stimulated by the TMS 253 
directly [52] . In terms of specificity, the same output can be elicited using a variety of 254 
stimulation sites. For instance, motor activity changes are associated with stimulation 255 
of the primary motor cortex M1 [50], supplementary motor area SMA [53] dorsal pre-256 
motor cortex PmD [54], as well as non-motor areas such as the cerebellum [55] and 257 
dorsolateral pre frontal cortex (DLPFC) [56].The potential for rTMS effects to last 258 
beyond the duration of stimulation this has been observed in a number of therapeutic 259 
applications in neurological disorders [57,58]. However, therapeutic applications of 260 
rTMS are outside the scope of this article. 261 
 262 
Safety considerations 263 
With the rapid increase in TMS applications in research and rehabilitation trials, 264 
safety in the clinical setting remains an important consideration. Although rare, 265 
seizure risk is mainly pertinent to rTMS protocols with an estimated risk in the region 266 
of 0.1% [59,60]. Most reported cases of seizures with TMS occurred before 1998 267 
when higher frequency trains were routinely administered and typically occurred in 268 
patients who had a previous history of seizures. Resting EEG abnormalities have 269 
been noted during TMS, though mostly in patients with epilepsy and they do not 270 
predict occurrence of seizures [61,62]. Isolated rare cases in patients have been 271 
reported since with concomitant seizure threshold lowering drugs (e.g. SSRI) or after 272 
sleep deprivation [59]. Risk of minor adverse events such as mild headache, tinnitus, 273 
cutaneous discomfort, neck muscle contraction, nausea, light headedness or 274 
syncope, unilateral eye pain and lacrimation remains less than 5%. To put this into 275 
perspective, the risk of seizures with penicillins and carbapenem drugs is up to 5% 276 
[63] and increases further with predisposing factors. To date, meta analyses of 277 
published treatment trials of TMS [64-66] have been reassuring and support safe use 278 
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9
of TMS in patients and healthy volunteers.  279 
 280 
TMS is considered safe in individuals with other stimulator devices such as VNS 281 
systems, cardiac pacemakers, and spinal cord stimulators provided that the TMS coil 282 
is not activated near the implanted wires [59]. Due to risk of induced currents, TMS 283 
should be avoided in patients with DBS, cochlear implants and with epidural 284 
electrodes. Additional safety studies are required to establish safe levels of currents 285 
that could be used with these implanted devices. Ex vivo studies have, reassuringly, 286 
demonstrated minimal, well below prescribed safety limits, heating of metal stents 287 
and aneurysm clips with rTMS protocols that have current approval for clinical uses 288 
[67,68]. However, caution is still warranted before more definitive evidence of safety 289 
becomes available from in vivo animal models and subsequently, human studies.  290 
 291 
Cortical dysfunction in neurodegenerative disease 292 
Assessment of cortical function in neurodegenerative disease has provided valuable 293 
pathophysiological insights and has the potential for diagnostic applications (Table 1). 294 
(i) Emerging biomarkers in amyotrophic lateral sclerosis (ALS) 295 
Determining the relationship between upper and lower motor neuron dysfunction 296 
remains key to understanding the pathogenesis of amyotrophic lateral sclerosis 297 
(ALS) [69,70]. Initial studies using single pulse TMS approaches demonstrated a 298 
reduction in motor threshold and the cortical silent period as features of early 299 
disease, providing preliminary evidence for cortical hyperexcitability in ALS 300 
[71,72]. Paired pulse techniques have, subsequently, provided more detailed 301 
evidence cortical excitability in terms of reduction or absence of SICI and 302 
increase in ICF [19]. SICI reductions precede electrophysiological evidence of 303 
peripheral neurodegeneration [73] as well as clinical evidence of lower motor 304 
neuron dysfunction in ALS [74]. SICI and ICF reduction are also seen in atypical 305 
variants of ALS with phenotypic predominance of lower motor neuron dysfunction 306 
[75], while these changes are not seen in ALS mimic disorders [76,77] such as 307 
spinobulbar muscular atrophy, despite a comparable disease burden. These 308 
findings strongly support the notion of cortical primacy in ALS [78]. Other 309 
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10
contributory evidence for this theory is the demonstration of reduced transcallosal 310 
inhibition in ALS [79]. Partial normalisation of SICI following the administration of 311 
riluzole [80], an antiglutaminergic drug used in ALS points to a pathogenic role for 312 
cortical hyperexcitability in ALS. This also highlights the potential application of 313 
TMS parameters in future clinical trials of ALS. 314 
SICI has been shown to be the greatest sensitivity and specificity for as a 315 
diagnostic marker in ALS [81]. Combining TMS measures with peripheral 316 
neurophysiological measures can, thus, potentially greatly increase the 317 
diagnostic accuracy in ALS [82]. 318 
 319 
(ii) Motor cortical alterations in Alzheimer’s disease (AD) 320 
The appearance of motor signs in AD is a late event in the natural history 321 
of the illness [83] and is likely due to the spread of pathology into the motor 322 
cortices and striatal structures with disease progression [84]. TMS studies 323 
have demonstrated a bimodal pattern for changes in the motor threshold in 324 
AD. RMT appears to be reduced in early AD and shows progressive 325 
decline despite anticholinergic treatment [85,86]. The early changes may be 326 
related to modulation of glutaminergic pathways by changes in activity of 327 
muscarinic cholinergic receptors [87], suggesting a degree of functional 328 
reorganisation [88,89]. In later stages of AD, the observed increase in MT is 329 
a likely due to cortical neuronal degeneration, indicative of more 330 
widespread cortical dysfunction [86]. Evidence regarding SICI changes in 331 
AD is more variable [47,90]. A more recent study has found alterations in 332 
LICI which correlate with cognitive scores [91].  333 
Loss of short latency afferent inhibition (SAI) appears to be a more consistent 334 
feature in AD [47,92,93], and seems to be normalised by administration of 335 
cholinesterase inhibitors [47]. SAI appears to be mediated by cholinergic neurons 336 
[94] and indirectly by GABAergic interneuronal inputs to cholinergic pyramidal 337 
neurons [95,96]. Muscarinic ACh receptor blockade with scopolamine specifically 338 
inhibits SAI, while not affecting the short interval intracortical inhibition, cortical 339 
silent period and intracortical facilitation, which are believed to be mediated by 340 
GABAergic interneurons [39].   Interestingly, SAI does not seem to be affected in 341 
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11
frontotemporal dementia (FTD), a disorder which does not directly involve the 342 
cholinergic system [97] unlike AD [98]. 343 
SAI changes have also been demonstrated in patients with Down’s syndrome 344 
who are at risk of developing early onset AD [99]. These findings have the 345 
potential for translation to the clinic for differentiating FTD from AD and are likely 346 
to be more cost effective than imaging modalities such as PET.  347 
TMS has also been used to demonstrate the disruption of long term potentiation 348 
(LTP) related cortical changes early on in the disease trajectory [100] in keeping 349 
with animal models of AD [101]. As such, LTP-like cortical alterations could 350 
provide a viable biomarker useful to assess synaptic impairment and predict 351 
subsequent cognitive decline progression in AD patients [102]. 352 
 353 
(iii)  Quantifying motor cortex dysfunction in Parkinson’s disease (PD) 354 
and other movement disorders 355 
While the degeneration of dopaminergic neurons in the substantia nigra and 356 
involvement of nigrostriatal pathways are the primary pathogenic changes in 357 
PD, functional changes in the motor cortices have been well recognised [103-358 
105]. SICI reductions have been reported in PD [106,107] particularly at 359 
higher stimulus intensities [108] suggesting a dysfunction in intracortical 360 
facilitatory pathways. Longitudinal evaluation of cortical dysfunction in PD 361 
revealed alterations in CSP between the less and more affected brain 362 
hemispheres which correlate with motor progression [109]. SAI reductions 363 
have also been documented in PD [110], particularly in the context of 364 
cognitive symptoms [111,112], suggesting a possible role for cholinergic 365 
pathways in the pathogenesis of cognitive dysfunction. TMS studies have also 366 
found alterations in interhemispheric inhibition, supporting the view that mirror 367 
movements in PD patients originate from crossed corticospinal projections 368 
rather than unmasking of ipsilateral projections PD [113,114]. In genetic forms 369 
of PD, distinct patterns have been found using TMS. Reduction in SICI 370 
recruitment have been found in asymptomatic Parkin mutation carriers, 371 
without significant changes in overall SICI, indicative of altered cortical 372 
function in asymptomatic carriers [115]. SICI reduction has not been noted in 373 
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Parkin patients. Given that SICI appears normal in Parkin patients and CMCT 374 
is prolonged, the reduced SICI recruitment may be indicative of a 375 
compensatory change in the motor cortex to subclinical dopaminergic 376 
dysfunction in mutation carriers.  377 
On the other hand, patients with leucine-rich repeat kinase2 (LRRK2), appear 378 
to have a markedly hyperexcitable motor cortex when compared to those with 379 
idiopathic PD, which is a likely contributor to functional changes in patients 380 
[116]. 381 
Motor cortical changes appear in the early stages if Huntington’s disease (HD) 382 
as shown by imaging studies [117,118] and pathological confirmation of 383 
neuronal loss in the primary motor and anterior cingulate cortices [119]. 384 
Moreover, motor symptomatology correlates with primary motor cortex 385 
involvement [119,120] while cognitive and behavioural features seem to 386 
correspond with changes other regions including prefrontal and anterior 387 
cingulate cortical areas [118-120]. TMS studies have captured early motor 388 
cortical dysfunction in HD including a higher MT and a reduced SAI, the latter 389 
being related to motor symptoms [121]. In addition, cortical hyperexcitability in 390 
terms of decreased SICI and increased ICF [122,123] have also been shown 391 
in HD, especially in the context of motor symptoms, indicating a potential role 392 
for both GABA [124] and glutaminergic pathways in HD pathogenesis. 393 
Atypical parkinsonian syndromes include progressive supranuclear palsy 394 
(PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) 395 
and are clinically and pathologically heterogeneous disorders. Motor cortical 396 
and corticospinal involvement is seen in these disorders to varying degrees 397 
[125-127]. Reduced SICI and abnormalities in interhemispheric inhibition have 398 
been demonstrated in PSP [128,129], the latter being more evident in the 399 
Richardson syndrome compared with parkinsonism predominant PSP [130]. 400 
RMT is elevated in CBD [128,131] and along with reduced SICI and may 401 
correlate with primary  motor cortex atrophy [132], indicating more severe 402 
neuronal loss in the motor cortex in CBD. Increased motor thresholds, 403 
reduced SICI and interhemispheric inhibition changes have also been 404 
demonstrated in MSA [128,133,134]. However, the correlation between these 405 
changes and clinical features remains less clear [135,136], and findings 406 
regarding interhemispheric inhibition are inconsistent [137]. Motor cortex 407 
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functional alterations have also been reported in PSP [129] and MSA [134]. 408 
Overall, findings from TMS studies suggest that primary motor cortex 409 
disinhibition may be an early process in PSP. In contrast, in CBD, global 410 
changes in inhibitory process may be secondary to neurodegeneration in the 411 
motor cortex.  412 
 413 
 414 
(iv) Novel insights in frontotemporal dementia (FTD)  415 
FTD encompasses three heterogeneous disorders including behavioural variant 416 
frontotemporal dementia (bvFTD), semantic dementia and progressive nonfluent 417 
aphasia. Characteristic phenotypic features in FTD include deficits in social 418 
cognition, executive function, language and behaviour. There is emerging 419 
evidence to suggest that ALS and FTD lie on a disease continuum with motor 420 
features prominent at one end and cognitive features at the other [138,139]. 421 
Concurrence of these two conditions in patients with C9orf72 mutation [140,141], 422 
occurrence of TAR DNA binding protein-43 (TDP-43) pathology in both conditions 423 
[142], clinical and electrophysiological evidence of upper motor neuron 424 
dysfunction in FTD [143], alongside evidence of behavioural and cognitive 425 
function in ALS are all supportive of this notion [144,145]. 426 
Motor cortex involvement in FTD occurs with the spread of pathology from frontal 427 
regions posteriorly [138], and anterior cingulate and M1 involvement on imaging 428 
overlaps with the imaging patterns seen in ALS [146]. TMS studies have shown 429 
central motor circuit abnormalities in FTD (reduced or absent MEP, increased 430 
MEP latency, increased CMCT) even in the absence of clinical evidence of 431 
pyramidal tract involvement, while MT and SAI have been found to be normal 432 
[97,143]. Earlier studies had found no significant changes in SICI and ICF, but 433 
more recent studies indicate SICI reductions in FTD [143,147]. SICI reductions in 434 
FTD seem to occur to a lesser degree than those seen in ALS. The preservation 435 
of cholinergic pathways evidenced by relatively normal SAI in conjunction with 436 
abnormalities in SICI and ICF have been utilised to distinguish FTD from AD 437 
[147]. 438 
 439 
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14
Understanding and predicting recovery after stroke 440 
Recovery from stroke is modulated by the intrinsic capacity of the brain to reorganise 441 
surviving brain networks. This process takes place through a variety of complex 442 
cellular processes including inflammation, growth factors, changes in excitatory and 443 
inhibitory neurotransmitters, transcriptional changes, axonal sprouting, neurogenesis, 444 
gliogenesis and synaptogenesis [148]. While there is variation related to stroke 445 
subtype and individual patient factors [149], severity of the initial deficit after stroke is 446 
the predominant predictor of recovery, referred to as proportional recovery. [150,151]. 447 
The ability to elicit and MEP response after stroke is a predictor of proportional 448 
recovery, regardless of the severity of initial impairment [152,153]. 449 
Studies in the motor domain indicate that patients with mild to moderate upper limb 450 
deficit are able to recover 70% of lost function in the first three months after stroke. 451 
However, in patients with severe stroke, recovery is proportional to initial severity in 452 
about half of the patients with the other half making no recovery at all. Stroke lesion 453 
induced structural and functional changes in the brain occur in the early phase after 454 
stroke coinciding with a period of heightened reorganisation, which can support 455 
some restoration of function referred to as spontaneous biological recovery [150]. 456 
While the precise biological mechanisms underlying spontaneous biological recovery 457 
are incompletely understood, evidence from animal models [154] suggests that 458 
behavioural training administered in a critical time window [155,156] can facilitate 459 
this process. The overarching goal of neuromodulatory approaches is to augment 460 
the process of spontaneous recovery and to change the trajectory of poor recovery 461 
to proportional recovery. 462 
Early after stroke, glutaminergic excitotoxicity leads to cell death and counteracts 463 
GABAergic inhibition [148,157,158] .The balance between glutaminergic 464 
excitotoxicity and GABAergic inhibition can influence regenerative processes and 465 
may reverse in later phases of recovery. TMS based approaches can be used to 466 
better understand these excitability changes and to guide therapeutic 467 
neuromodulation in an appropriate time window. 468 
Increased transcallosal inhibition  from the contralesional hemisphere [159,160], may 469 
suppress excitability of the lesioned hemisphere. More recent work has determined 470 
that transcallosal inhibition from ipsilesional to contralesional hemisphere may 471 
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increase in chronic stroke patients [161]. Both these patterns seem to interfere with 472 
functional recovery [162,163]. A meta-analysis of TMS studies of post stroke cortical 473 
changes found no asymmetry in interhemispheric inhibition in stroke patients in the 474 
small number of available studies. In terms of experimental rehabilitation 475 
programmes, facilitating affected M1 excitability directly may be more beneficial than 476 
suppressing unaffected M1 excitability to promote post-stroke recovery [164]. 477 
Contralesional activity may play some role in improving function [165,166]. An 478 
important determinant of recovery that interacts with excitability changes is the 479 
extent of structural damage to key pathways [167,168]. Current understanding of 480 
recovery is well described under the ‘bimodal balance recovery model’ [169]. This 481 
model suggests that changes in interhemispheric activity interact with the extent of 482 
surviving neural pathways, referred to as the ‘structural reserve’. Thus, in strokes 483 
with a smaller deficit and a large structural reserve, interhemispheric imbalance 484 
predicts poorer outcomes. In these patients, restoration of activity towards the 485 
physiological equilibrium should be a primary therapeutic goal. On the other hand, in 486 
strokes with more severe deficits and lower structural reserve, the interhemispheric 487 
imbalance may allow some compensatory changes leading to varying amounts of 488 
functional recovery. 489 
TMS has been used to interrogate cortical reorganisation in patients with stroke and 490 
can be useful for prognosis. The ability to elicit an MEP response after stimulation of 491 
the lesioned motor cortex might help predict motor function recovery [170,171]. 492 
Conversely, inability to elicit an MEP after ipsilesional TMS and increased MEP after 493 
contralesional stimulation seems to predict poorer recovery of motor function 494 
[172,173]. Likewise, appearance of MEP responses after ipsilesional stimulation, 495 
when MEP responses were not elicited previously, is associated with better 496 
functional recovery [174]. Alterations in cortical excitability in the lesioned 497 
hemisphere have been demonstrated using TMS in stroke patients [175] (Figure 3). 498 
Prolongation of CSP in the lesioned hemisphere, indicating increased intracortical 499 
inhibition, has been demonstrated after subcortical stroke [176]. On the other hand, 500 
SICI and long interval intracortical inhibition (LICI) are suppressed in the affected 501 
hemisphere [177-179], while ICF seems to be unaltered after stroke [178,180-182]. 502 
Contralesional changes in excitability are less marked. MEP responses and motor 503 
thresholds appear to be largely intact [170,181,183-186] in the paretic limb, while 504 
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16
some studies suggest alteration in SICI [177,178,181,187]. Indeed, recent work 505 
evaluating longitudinal changes in cortical excitability after stroke using TMS from as 506 
early as the first week after stroke up to a year afterwards, shows that contralesional 507 
hyperexcitability evolves differently in patients with different stroke types and may 508 
have an adaptive role when ipsilesional pathways are significantly disrupted 509 
[179,187]. SICI is decreased in both the affected and unaffected hemisphere after 510 
stroke, but tends to remain suppressed only in patients with larger strokes and more 511 
severe clinical deficits [187]. 512 
Clearer understanding of neuroplastic changes underlying recovery is essential for 513 
development of personalised rehabilitation strategies for patients and application in 514 
clinical trials [168] accounting for the topography of damaged and surviving neural 515 
pathways after a stroke. The predicting recovery potential (PREP) algorithm 516 
illustrates how a sequential consideration of clinical, TMS and imaging factors can 517 
provide prognostic information for motor function recovery in stroke [188,189]. The 518 
key factors incorporated into this algorithm are the extent of clinical weakness, ability 519 
to elicit an MEP response in the paretic hand and the degree of corticospinal tract 520 
involvement on diffusion tensor imaging. Such a sequential approach has been 521 
shown to increase therapy efficiency while achieving good clinical outcomes in post 522 
stroke rehabilitation [153]. 523 
In summary, TMS has evolved as a readily accessible, non-invasive 524 
neurostimulation tool with potentially wide ranging diagnostic and prognostic 525 
applications. Separately, TMS provides a unique research tool to investigate 526 
pathophysiological changes in the cortex in stroke and neurodegenerative disorders. 527 
Applications of TMS based biomarkers in clinical trials are likely to emerge. In an 528 
evolving era of precision medicine, TMS based approaches have the potential to 529 
make personalised rehabilitative and restorative interventions in the future a reality, 530 
with better understanding of mechanisms of loss of function in neurodegeneration 531 
and the trajectory of recovery in stroke. 532 
 533 
 534 
 535 
 536 
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 537 
Table 1 Cortical function alterations across neurodegenerative 538 
disorders  539 
 540 
 RMT % MEP % SICI (%) ICF (%) CSP (ms) CMCT 
(ms) 
SAI (%) 
ALS 
[19,70,72] 
Reduced 
Increased 
Inexcitabl
e 
Increased 
Normal 
Reduced 
 
Increased 
Normal 
Reduced 
 
Increased 
Normal 
N/A 
AD 
[47,86,90,92,
93]  
Reduced 
Increased 
Increased 
Normal 
Reduced 
Normal 
Normal Normal 
Reduced 
Normal Reduced 
PD 
[103,106,110
-112] 
Normal Normal Reduced 
Normal 
Normal Reduced 
Normal 
Normal Reduced 
Increased 
Normal 
HD [121,122]  Increas d 
 
Reduced Reduced Increased 
 
Increased 
Reduced 
Normal Reduced 
FTD [97,147]  Normal Absent 
Reduced 
Reduced 
Normal 
Normal Normal Increased 
Normal 
Normal 
MSA 
[128,133,134
] 
Increased 
Normal 
Normal Reduced Normal Increased Normal Reduced 
Normal 
PSP [128-
130]  
Normal Increased Reduced Normal Reduced Normal Normal 
 541 
ALS (amyotrophic lateral sclerosis), FTD (frontotemporal dementia), AD (Alzheimer’s disease), PD (Parkinson’s disease), PSP 542 
(progressive supranuclear palsy), MSA (multiple system atrophy), HD (Huntington’s disease), RMT (resting motor threshold), 543 
MEP (motor evoked potential), CMCT (central motor conduction time), CSP (cortically silent period), SICI (short interval 544 
intracortical inhibition), ICF (intracortical facilitation), SAI (short latency afferent inhibition) 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
 580 
 581 
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Figure legends 613 
 614 
Figure 1. TMS using a circular coil showing the lines of flux of the magnetic field and 615 
directions of stimulating and induced currents. 616 
 617 
Figure 2. The paired-pulse threshold tracking TMS (TT-TMS) paradigm to measure 618 
cortical excitability. 2a) Short interval intracortical inhibition (SICI) occurs at an 619 
interstimulus interval (ISI) of 0-7 ms while intracortical facilitation (ICF) occurs at an 620 
ISI of 7-10 ms. 2b) TMS coil placed over the vertex stimulates the motor cortex and 621 
the response is recorded from the opposite abductor pollicis brevis muscle. 2c) 622 
Change in stimulus intensity required to achieve a target motor evoked potential 623 
(MEP) of 0.2 mV(±20%) is used to quantify the SICI and ICF. 624 
 625 
Figure 3. TMS may be used to stimulate the perilesional cortex after stroke and/or 626 
suppress excitability of the opposite hemisphere. 627 
 628 
 629 
 630 
 631 
 632 
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Figure 1. TMS using a circular coil showing the lines of flux of the magnetic field and directions of stimulating 
and induced currents.  
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Figure 2. The paired-pulse threshold tracking TMS (TT-TMS) paradigm to measure cortical excitability. 2a) 
Short interval intracortical inhibition (SICI) occurs at an interstimulus interval (ISI) of 0-7 ms while 
intracortical facilitation (ICF) occurs at an ISI of 7-10 ms. 2b) TMS coil placed over the vertex stimulates the 
motor cortex and the response is recorded from the opposite abductor pollicis brevis muscle. 2c) Change in 
stimulus intensity required to achieve a target motor evoked potential (MEP) of 0.2 mV(±20%) is used to 
quantify the SICI and ICF.  
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Figure 3. TMS may be used to stimulate the perilesional cortex after stroke and/or suppress excitability of 
the opposite hemisphere.  
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